Roche ratchets up Alzheimer's work in growing neuroscience pipeline

Luca Santarelli, Roche's head of neuroscience

Roche ($RHHBY), known as the world's largest provider of cancer drugs, wants to be a leading player in therapies for Alzheimer's disease specifically and neuroscience more broadly. As Roche neuroscience head Luca Santarelli tells Pharmalot, the Swiss drug giant now has about a dozen clinical-stage programs in his group, and the pipeline is growing. With gantenerumab, the company is focusing on patients who start showing signs of Alzheimer's before dementia sets in. The focus on treating patients at an early stage is the name of the game for Roche's top Alzheimer's program. Q&A